<DOC>
	<DOCNO>NCT00919984</DOCNO>
	<brief_summary>Most patient advanced ovarian cancer suffer recurrence . Therefore , adjuvant therapy recommend patient advanced ovarian cancer . Traditionally , intravenous paclitaxel + carboplatin standard adjuvant therapy . Recently , intraperitoneal combination chemotherapy report effective ovarian cancer . We attempt evaluate efficacy feasibility standard intravenous paclitaxel + carboplatin plus intraperitoneal paclitaxel chemotherapy .</brief_summary>
	<brief_title>Efficacy Study Additional Intraperitoneal Chemotherapy Treat Ovarian Cancer</brief_title>
	<detailed_description>Epithelial ovarian cancer lead cause death gynecologic malignancy worldwide . The recommended treatment include primary surgery diagnosis , stag , cytoreduction , follow chemotherapy . Epithelial ovarian cancer sensitive cytotoxic drug solid tumor , patient advance ovarian cancer recommend treatment postoperative adjuvant chemotherapy . The recommended initial chemotherapy generally platinum taxane combination give intravenous infusion every 3 week 6 course . This treatment result complete remission 50 % ovarian cancer patient pathologic complete response 25~30 % patient . However patient advanced ovarian cancer suffer recurrence primary treatment , median progression free survival 15.5-22months , median overall survival 31-44months . As residual ovarian cancer surgery initial recurrence primarily confine abdomen , intraperitoneal administration chemotherapy propose several decade ago . In 2006 , Armstrong , et al. , report improvement overall survival ovarian cancer patient optimal surgical debulking follow intraperitoneal paclitaxel + cisplatin chemotherapy . The National Cancer Institute ( NCI ) United States recommend consider intraperitoneal chemotherapy optimally debulking patient . In Korea , however , study postoperative adjuvant intraperitoneal chemotherapy optimally debulked ( residual mass &lt; 1cm ) advance ovarian cancer patient . Therefore investigator tend evaluate efficacy feasibility postoperative adjuvant intraperitoneal chemotherapy . ( standard intravenous paclitaxel+carboplatin plus intraperitoneal paclitaxel chemotherapy )</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Age &gt; =20 &lt; =75 2 . Histologically confirm epithelial ovarian cancer , primary peritoneal carcinoma , tubal cancer 3 . Stage 3 4 4 . WBC &gt; = 3500/mm3 , ANC &gt; = 1500/mm3 , platelet &gt; = 100000/mm3 , hemoglobin &gt; = 10 g/dl 5 . Serum creatinine &lt; = upper normal limit * 1.25 6 . Total bilirubin &lt; = 1.5mg/mm3 , ALT/AST &lt; = upper normal limit * 3 , ALP &lt; = upper normal limit * 3 7 . Adequate compliance geographical closeness make adequate followup possible 8 . GOG performance status 02 9 . Anticipated survival &gt; = 3 month 10. Who agree participate study sign informed consent form Exclusion criterion : 1 . History chemotherapy radiotherapy abdomen/pelvis area 2 . Pleural/pericardial effusion , ascites cause respiratory difficulty &gt; = NCICTCAE grade 2 3 . History cancer within 5 year 4 . History unapproved therapy within 30 day enrollment 5 . Other serious disease could threat safety participant impair ability participant complete participation .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>OVARIAN NEOPLASMS</keyword>
	<keyword>ADJUVANT CHEMOTHERAPY</keyword>
	<keyword>INTRAPERITONEAL CHEMOTHERAPY</keyword>
</DOC>